ProCE Banner Activity

Phase II Trial of Daratumumab Plus Ixazomib/Lenalidomide/Dose-Modified Dexamethasone in Newly Diagnosed MM

Slideset Download
Conference Coverage
The addition of daratumumab to triplet IRd induction therapy with modified-dose dexamethasone was associated with rapid responses that deepened over time.

Released: December 18, 2019

Expiration: December 16, 2020

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Celgene

Dova Pharmaceuticals

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Karyopharm Therapeutics

Loxo Oncology subsidiary of Eli Lilly

Pharmacyclics an AbbVie Company